Fresenius SE & Co. KGaA (0OO9) Price & Analysis
0OO9 Stock Chart & Stats
- Day’s Range
- EUR 47.10 - EUR 47.89
- 52-Week Range
- EUR 35.13 - EUR 52.82
- Previous Close
- EUR 46.93
- Volume
- 1,231
- Average Volume (3M)
- 235.73K
- Market Cap
- EUR 26.65B
- Enterprise Value
- EUR 33.35B
- Total Cash (Recent Filing)
- EUR 1.28B
- Total Debt (Recent Filing)
- EUR 11.42B
- Price to Earnings (P/E)
- 17.4
- Beta
- 1.04
- Next Earnings
- Nov 04, 2026
- EPS Estimate
- 0.78
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- 2.20%
Bulls Say, Bears Say
Bulls Say
Profitability Recovery
The return to positive net profitability, supported by solid operating and EBITDA margins, indicates that the business has rebuilt earnings power after the 2023 loss. If maintained across Helios, Kabi and FMC-related operations, this recovery can support reinvestment and strengthen financial resilience over the next several quarters.
Meaningful Deleveraging
The substantial reduction in debt relative to equity lowers financial risk and gives Fresenius greater flexibility to fund operations, invest in its healthcare businesses, or withstand pressure in reimbursement and utilization. A stronger balance sheet also makes the earnings recovery more durable than one dependent on higher leverage.
Biosimilar Platform Expansion
The mAbxience-Sandoz agreement expands Fresenius’s exposure to biosimilars by combining development and manufacturing capabilities with global commercialization reach. Although financial terms are undisclosed and the product remains a candidate, the arrangement could broaden Kabi-related growth opportunities and patient access over time.
Bears Say
Weakening Cash Conversion
Positive cash flow is being generated, but the decline in free cash flow and conversion at roughly half of net income reduce confidence that accounting earnings are translating consistently into distributable cash. Persistent working-capital or capital-spending demands could constrain debt reduction, investment, and shareholder returns.
Uneven Revenue Trajectory
Current revenue momentum benefits from recovery versus the weak 2023 base, yet the sharp prior decline shows that Fresenius has not established a consistently smooth growth path. Uneven top-line performance can make capacity planning and margin improvement harder and leaves results more dependent on recovery execution.
Returns Remain Below Prior Peaks
The rebound in returns is encouraging, but ROE remains below the earlier 2021 level and the recovery has not restored prior profitability highs. This suggests asset efficiency or operating performance is not yet fully normalized, which may limit the pace at which Fresenius compounds earnings from its healthcare platform.
Fresenius SE & Co. KGaA News
0OO9 FAQ
What was Fresenius SE & Co. KGaA’s price range in the past 12 months?
What is Fresenius SE & Co. KGaA’s market cap?
When is Fresenius SE & Co. KGaA’s upcoming earnings report date?
How were Fresenius SE & Co. KGaA’s earnings last quarter?
Is Fresenius SE & Co. KGaA overvalued?
Does Fresenius SE & Co. KGaA pay dividends?
What is Fresenius SE & Co. KGaA’s EPS estimate?
How many shares outstanding does Fresenius SE & Co. KGaA have?
What happened to Fresenius SE & Co. KGaA’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Fresenius SE & Co. KGaA?
What is the TipRanks Smart Score and how is it calculated?
Fresenius SE & Co. KGaA Stock Smart Score
Company Description
Fresenius SE & Co. KGaA
Fresenius SE & Co. KGaA operates as a diverse healthcare enterprise, supplying a comprehensive array of products and services primarily focused on dialysis, hospital management, and outpatient medical care. Its activities are structured across four main divisions: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care division is dedicated to individuals living with chronic kidney failure, offering essential items like dialyzers, hemodialysis machines, and related disposable supplies, alongside various dialysis-specific services. Fresenius Kabi concentrates on the therapeutic treatment and care of ill patients. Its extensive product range includes intravenous pharmaceuticals, such as generic drugs for oncology, anesthetics, pain relief, anti-infectives, and critical care. Additionally, it provides parenteral and enteral nutritional products, infusion solutions, and blood volume expanders for infusion therapy. The segment also develops biosimilars—biological medicines for autoimmune and cancer conditions—and manufactures medical devices and disposables crucial for administering IV generics, infusion treatments, and clinical nutrition. Transfusion products for blood component collection and corporeal therapies are also part of its offerings. Fresenius Helios manages significant healthcare operations, encompassing 90 hospitals, approximately 130 outpatient clinics, and 6 prevention centers throughout Germany. In Spain, its presence includes 49 hospitals, 88 outpatient clinics, and around 300 risk prevention centers. This segment also delivers fertility treatment services through 33 clinics and an additional 39 sites located across 10 countries on three continents. Finally, the Fresenius Vamed division specializes in project management and service delivery for hospitals and other healthcare facilities. Its offerings span project development, meticulous planning, and turnkey construction solutions. Furthermore, it provides ongoing maintenance, technical oversight, and operational management services. The company, initially known as Fresenius SE, officially changed its name to Fresenius SE & Co. KGaA in January 2011. Founded in 1912, Fresenius SE & Co. KGaA maintains its corporate headquarters in Bad Homburg vor der Höhe, Germany.
- Sector
- General
- Industry
- Medical - Care Facilities
- CEO
- Michael Sen
- Employees
- 178,486
- Website
- www.fresenius.com
- Address
- Else-Kroener-Strasse 1, Bad Homburg vor der Höhe, HE, 61352, DE
Fresenius SE & Co. KGaA (0OO9) Earnings & Revenues
0OO9 Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 14 | 3 | 5 |
| Technical Analysis | 2 | 3 | 5 |
| Moving Averages | 12 | 0 | 0 |